Hólyagrák: vizsgálatok itt: Kína
167 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleRC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 55
- Run by
- Zhujiang Hospital
See details and how to joinNCT06341400 - 1/2. fázisTaking peopleSymbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Where
- Beijing, Nanjing, Ningbo, Tianjin
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Pfizer
See details and how to joinNCT07421700 · EU 2025-523523-21-00 - 2. fázisNot yet taking people in KínaResponse-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 70
- Run by
- Tongji Hospital
See details and how to joinNCT07865611 - 3. fázisTaking peopleA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Nanjing, Nanning, Ningbo, Shanghai, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00 - 2. fázisTaking peopleTrop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
- Where
- Kunming
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT07848854 - 3. fázisTaking peopleDisitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 192
- Run by
- Peking University First Hospital
See details and how to joinNCT07498907 - 1/2. fázisNot yet taking people in KínaTrop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
- Where
- Kunming
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT07800507 - 2. fázisNot yet taking people in KínaA Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 42
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07837622 - 1. fázisTaking peopleRimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 12
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07835035 - 2. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 114
- Run by
- Ractigen Therapeutics.
See details and how to joinNCT07777848 - 2. fázisNot yet taking people in KínaToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
- Where
- Wenzhou
- Életkor
- 18 év and over
- People
- 106
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07189793 - 3. fázisTaking peopleA Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
- Where
- Beijing, Guangzhou
- Életkor
- 18 év and over
- People
- 750
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07726992 - 1/2. fázisTaking peopleA Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
- Where
- Beijing, Nanjing
- Életkor
- 18 év and over
- People
- 180
- Run by
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07468851 - No phaseTaking peopleTrop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
- Where
- Kunming
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT06972771 - 2. fázisNot yet taking people in KínaTR115 in ARID1A-Mutated Advanced Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- Tarapeutics Science Inc.
See details and how to joinNCT07793318 - 1. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure
- Where
- Changsha
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT07783815 - No phaseNot yet taking people in KínaHome-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application
- Where
- Nanjing
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Nanjing First Hospital, Nanjing Medical University
See details and how to joinNCT07781956 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - 2/3. fázisTaking peopleStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Where
- Beijing, Chengdu, Guangzhou
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07129993 - 3. fázisTaking peopleA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 453
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07393542 - 2/3. fázisNot yet taking people in KínaBladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 114
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07756008 - 1. fázisTaking peopleA Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
- Where
- Chengdu
- Életkor
- 18 év and over
- People
- 18
- Run by
- Jecho Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07483970 - 2. fázisTaking peopleNeoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
- Where
- Huanggang, Jingzhou, Shiyan, Wuhan, Xiangyang, Yichang
- Életkor
- 18 év to 75 év
- People
- 54
- Run by
- Zhiquan Hu
See details and how to joinNCT07741448 - 2/3. fázisTaking peoplePhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Tianjin, Wenzhou, Wuhan, Xiamen, Yantai, Zhengzhou
- Életkor
- 18 év and over
- People
- 470 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07106762 - 1. fázisTaking peopleA Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
- Where
- Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év to 70 év
- People
- 174
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07518043